HIT/HITT and alternative anticoagulation: Current concepts

British Journal of Anaesthesia

Volumn 90, Issue 5, 2003, Pages 676-685

  Pravinkumar, E ^a   Webster, N R ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Blood, anticoagulants, heparin; Blood, coagulation

Indexed keywords

ANCROD; ANTIBODY; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; DANAPAROID; DESULFATOHIRUDIN; ECARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRULOG; ILOPROST; IMMUNOGLOBULIN G; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROSTACYCLIN DERIVATIVE; REVASE; THROMBIN; THROMBIN INHIBITOR; WARFARIN;

ANTIBODY PRODUCTION; ANTICOAGULATION; ANTIGEN BINDING; BLEEDING; BLOOD CLOTTING TIME; BRADYCARDIA; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GANGRENE; HUMAN; HYPOTENSION; KIDNEY DISEASE; LABORATORY TEST; LIVER METABOLISM; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT CONTRAINDICATION;

EID: 0038732437     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aeg063     Document Type: Review

References (82)

1. Ahmad S, Walenga JM, Jeske WP, et al. Functional heterogeneity of antiheparin-platelet-factor 4 antibodies: implications in the pathogenesis of the HIT syndrome. Clin Appl Thromb Hemost 1999; 5: S32-7
2. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-6
3. Amiral J. Antigens involved in heparin induced thrombocytopenia. Semin Haematol 1996; 36 (Suppl 1): 7-11
4. Arepally G, McKenzie SE, Jiang X-M, et al. FcγRIIa H/R131 polymorphism, subclass specific IgG antiheparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood 1997; 89: 370-5
5. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 2001; 98: 1252-4
6. Babcock RB, Dumper CW, Scharfman WB. Heparin-induced thrombocytopenia. N Engl J Med 1976; 295: 237-41
7. Barcelona R. Type II HIT new treatment options-Cleveland Clinic Center For Continuing Education. Pharmacother Update 2001; 4: http://www.clevelandclinicmeded.com/medical_info/pharmacy/septoct2001/ thrombocytopenia.htm
8. Baughman RP, Lower EE, Flessa HC, et al. Thrombocytopenia in intensive care unit. Chest 1993; 104: 1243-7
9. Boons DM, Michels JJ, Stibbe J, et al. Heparin-induced thrombocytopenia and antithrombotic therapy. Lancet 1994; 344: 1296
10. Brieger DB, Mak K-H, Kottke-Marchant K, et al. Heparin induced thrombocytopenia. J Am Coll Cardiol 1998; 31: 1449-59
11. Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995; 89: 431-9
12. Chong BH, Fawaz I, Chesterman CN, et al. Heparin-induce thrombocytopenia: mechanism of interaction of the heparin dependant antibody with platelets. Br J Haematol 1989; 73: 235-40
13. Chong BH, Murray B, Berndt M, et al. Plasma P-selectin is increased in thrombotic consumptive platelet disorder. Blood 1994; 83: 1535-41
14. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial cell injury in heparin associated thrombocytopenia. N Engl J Med 1987; 316: 58
15. Deitcher SR, Carman TL. Heparin-induced thrombocytopenia: natural history, diagnosis, and management. Vasc Med 2001; 6: 113-19
16. Demers C, Ginsberg JS, Brill-Edwards P, et al. Rapid anticoagulation using ancrod for heparin induced thrombocytopenia. Blood 1991; 78: 2194-7
17. Denomme GA, Warkentin TE, Horsewood P, et al. Activation of platelets by sera containing IgG1 heparin-dependant antibodies: an explanation for the predominance of the FcγRIIa 'low responder' (his131) gene in patients with heparin induced thrombocytopenia. J Lab Clin Med 1997; 130: 278-84
18. Deykin D. The use of heparin. N Engl J Med 1969; 279: 937-8
19. Eichler P, Budde U, Haas S, et al. First workshop for detection of heparin-induced antibodies: validation of the heparin induced platelet activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost 1999; 81: 625-9
20. Fondu P. Heparin associated thrombocytopenia: an update. Acta Clin Belg 1995; 50: 343-57
21. Funk S, Eichler P, Albrecht D, et al. Heparin-induced thrombocytopenia (HIT) in orthopaedic patients: a prospective cohort trial comparing UFH and LMWH. Ann Haematol 2000; 79 (Suppl 1): A92
22. Fuster V, Verstraete M. Haemostasis, thrombosis, fibrinolysis, and cardiovascular disease. In: Braunwauld E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: W. B. Saunders, 1997; 1809-42
23. Greinacher A. Heparin associated thrombocytopenia. Biomed Prog 1994; 7: 53-6
24. Greinarcher A, Volpel H, Janssens U, et al. for the HIT Investigators Group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73-80
25. Greinarcher A, Janssens U, Berg G, et al. for the Heparin Associated Thrombocytopenia Study (HAT) investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin induced thrombocytopenia. Circulation 1999; 100: 587-93
26. Greinacher A, Potzsch B, Amiral J, et al. Heparin associated thrombocytopenia: isolation of the antibody and characterisation of a multimolecular PF-4 heparin complex as the major antigen. Thromb Haemost 1994; 93: 81-8
27. Greinacher A, Michels I, Kiefel V, et al. A rapid and sensitive test for diagnosing heparin associated thrombocytopenia. Thromb Haemost 1991; 66: 734-6
28. Greinacher A, Amiral J, Dummel V, et al. Laboratory diagnosis of heparin associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme linked immunosorbent assay. Transfusion 1994; 34: 381-5
29. Greinacher A, Eichler P, Lubenow N, et al. Heparin induced thrombocytopenia with thromboembolic complications: meta analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846-51
30. Greinacher A, Drost W, Michels I, et al. Heparin associated thrombocytopenia: successful therapy with the heparinoid danaparoid sodium in a patient showing cross-reaction to LMW heparins. Ann Haematol 1992; 64: 40-2
31. Griffiths E, Dzik WH. Assays for heparin induced thrombocytopenia. Transfus Med 1997; 7: 1-11
32. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5 mg and 10 mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 15: 133-6
33. Hirsch J, Anand S, Halperin J, et al. Guide to anticoagulant therapy-heparin: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 103: 2994-3018
34. Hursting M, Alford K, Becker J, et al. Novastan (brand of argatroban): a small molecule direct thrombin inhibitor. Semin Thromb Haemost 1997; 23: 503-16
35. Januzzi JL, Jang IK. Fundamental concepts in the pathobiology of heparin-induced thrombocytopenia. J Thromb Thrombolysis 2000; 10: S7-11
36. Jang I, Brown D, Giugliano R, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) study. J Am Coll Cardiol 1999; 33: 1879-85
37. Kelton J, Smith J, Warkentin T, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 3232-9
38. Kelton J, Sheridan D, Santos A, et al. Heparin induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925-30
39. Keng T, Chong B. Short report: heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with rhirudin. Br J Haematol 2001; 114: 394-6
40. Kibbe UR, Rhee RY. Heparin induced thrombocytopenia: pathophysiology. Semin Vasc Surg 1996; 9: 284-91
41. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100: 536-40
42. Koster A, Hansen R, Kuppe H, et al. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1 year experience in 57 patients. J Cardiothorac Vasc Anesth 2000; 14: 243-8
43. Laster J, Cikrit D, Walker N, Silver D. The heparin induced thrombocytopenia syndrome: an update. Surgery 1987; 102: 763-70
44. Lewis B, Wallis D, Mathai W for the ARG-911 study investigators. Argatroban anticoagulant therapy in patients with heparin induced thrombocytopenia. Circulation 2001; 103: 1838
45. Mikhailov D, Young HC, Linhardt RJ, et al. Heparin dodecasaccharide binding to platelet factor 4 and growth related protein alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia. J Biol Chem 1999; 274: 25317-29
46. Mohiuddin SM, Hilleman DE, Destache CJ, et al. Efficacy and safety of early versus late initiation of warfarin during heparin therapy in acute thromboembolism. Am Heart J 1992; 123: 729-32
47. Nand S, Wong W, Yeun B, et al. Heparin induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Haematol 1997; 56: 12-6
48. Abbott Laboratories. New Drug Application 20-883. North Chicago, IL: Abbott Laboratories, 2001; 4-27
49. Newman PM, Chong BH. Heparin induced thrombocytopenia: new evidence for dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000; 96: 182-7
50. Ofosu FA, Esmon CT, Blajchman MA, et al. Unfractioned heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J 1989; 257: 143-50
51. SmithKline Beecham. Package insert. Argatroban. North Chicago, IL: SmithKline Beecham, 2000
52. Parent F, Bridey F, Dreyfus M, et al. Treatment of severe venous thromboembolism with intravenous hirudin (HBW 023): an open pilot. Thromb Haemost 1993; 70: 386
53. Medical Economics Company. Heparin. In: Physician's Desk Reference. Montvale, NJ: Medical Economics Company, 1998: 3044
54. Potzsch B, Hund S, Madlener K, et al. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res 1997; 86: 373-83
55. Pouplard C, May MA, Lochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients with unfractioned heparin or a low molecular weight heparin: clinical implications for heparin induced thrombocytopenia. Circulation 1999; 99: 2530-6
56. Rhodes GR, Dixon RH, Silver D. Heparin induced thrombocytopenia with thrombotic and haemorrhagic manifestations. Surg Gynecol Obstet 1973; 136: 409-16
57. Schulman LN, Branwauld E, Rosenthal DS. Haematological-oncological disorders and heart disease. In: Braunwauld E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: W. B. Saunders, 1997; 1786-808
58. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin induced thrombocytopenia. Blood 1986; 67: 27-30
59. Stringer KA, Lindenfield J. Hirudins: antithrombin anticoagulants. Ann Pharmacother 1992; 26: 1535
60. Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognise different epitopes on heparin platelet factor 4. Blood 1998; 91: 916-22
61. Swan M, Hursting M. The pharmacokinetics and pharmacodynamics of argatroban: effect of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-29
62. Villanueva GB, Danishefsky I. Evidence for a heparin-induced conformational change on antithrombin. Biochem Biophys Res Commun 1977; 74: 803-9
63. Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-8
64. Visentin GP, Aster RH. Heparin induced thrombocytopenia and thrombosis. Curr Opin Haematol 1995; 2: 351-7
65. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106: 629-35
66. Wallis DE, Quintos R, Wehrmacher W, Messmore H. Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. Chest 1999; 116: 1333-8
67. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1-7
68. Warkentin TE, Kelton JG. Interaction of heparin with platelets, including heparin induced thrombocytopenia. In: Bounmeaux H, ed. Low Molecular Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases. Fundamentals and Clinical Cardiology. New York: Marcel Dekker, 1994; 75-127
69. Warkentin TE. Heparin induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost 1999; 82 (Suppl): 439-47
70. Warkentin TE, Levine MN, Hirsch J, et al. Formation of heparin-induced thrombocytopenia IgG without thrombocytopenia: analysis of a clinical trial. Blood 1995; 86 (Suppl 1): 537
71. Warkentin TE. Heparin induced skin lesions. Br J Haemotol 1996; 92: 494-7
72. Warkentin TE, Levine MN, Hirsch J, et al. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractioned heparin. N Engl J Med 1995; 332: 1330-5
73. Warkentin TE. Clinical picture of heparin induced thrombocytopenia. In: Warkentin TE, Greinarcher A, eds. Heparin Induced Thrombocytopenia. New York: Marcel Dekker, 2000; 43-80
74. Warkentin TE, Kelton JG. A 14-year study of heparin induced thrombocytopenia. Am J Med 1996; 101: 502-7
75. Warkentin TE, Elavathil LJ, Hayward CP, et al. Pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804-12
76. Warkentin TE. Limitations of conventional treatment options for heparin induced thrombocytopenia. Semin Haematol 1998; 35 (Suppl 4): 17
77. Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin induced thrombocytopenia. Blood 1994; 84: 3691-9
78. Warkentin TE, Kelton JG. Temporal aspects of heparin induced thrombocytopenia. N Engl J Med 2001; 344: 1286-92
79. Weismann R, Tobin RW. Arterial embolism occurring during systemic heparin therapy. Arch Surg 1958; 76: 219-27
80. Weitz JL, Hudoba M, Massel D, et al. Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385
81. Weitz JL, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition from heparin-antithrombin but susceptible to inactivation by antithrombin independent inhibitors. Circulation 1999; 99: 73
82. Ziporen L, Li ZQ, Park KS, et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998; 92: 3250-9